AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 104 filers reported holding AKERO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $20,310,000 | -1.0% | 596,483 | -72.5% | 4.70% | -19.6% |
| Q2 2022 | $20,522,000 | -33.4% | 2,171,664 | 0.0% | 5.84% | -14.5% |
| Q1 2022 | $30,816,000 | -32.9% | 2,171,664 | 0.0% | 6.83% | -17.4% |
| Q4 2021 | $45,931,000 | -6.6% | 2,171,664 | -1.3% | 8.28% | +68.9% |
| Q3 2021 | $49,187,000 | -9.9% | 2,200,778 | 0.0% | 4.90% | -24.0% |
| Q2 2021 | $54,601,000 | -23.0% | 2,200,778 | -10.0% | 6.44% | -4.3% |
| Q1 2021 | $70,909,000 | +12.4% | 2,444,311 | 0.0% | 6.74% | +21.1% |
| Q4 2020 | $63,063,000 | -16.2% | 2,444,311 | 0.0% | 5.57% | -51.3% |
| Q3 2020 | $75,260,000 | -4.1% | 2,444,311 | -22.4% | 11.44% | -82.5% |
| Q2 2020 | $78,498,000 | +17.5% | 3,150,019 | 0.0% | 65.27% | +14.7% |
| Q1 2020 | $66,780,000 | -23.6% | 3,150,019 | -20.1% | 56.91% | +51.8% |
| Q4 2019 | $87,460,000 | -2.8% | 3,940,543 | -0.4% | 37.50% | -12.2% |
| Q3 2019 | $89,973,000 | +18.8% | 3,954,858 | 0.0% | 42.68% | +27.0% |
| Q2 2019 | $75,736,000 | – | 3,954,858 | – | 33.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $169,134,000 | 18.83% |
| venBio Partners LLC | 2,444,311 | $70,909,000 | 6.74% |
| Versant Venture Management, LLC | 617,727 | $17,920,000 | 3.49% |
| Redmile Group, LLC | 2,513,746 | $72,924,000 | 1.03% |
| Boxer Capital, LLC | 831,495 | $24,122,000 | 0.82% |
| Integral Health Asset Management, LLC | 85,000 | $2,466,000 | 0.70% |
| Vivo Capital, LLC | 673,280 | $19,532,000 | 0.69% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 32,000 | $928,000 | 0.51% |
| Cormorant Asset Management, LP | 742,549 | $21,541,000 | 0.48% |
| HHLR ADVISORS, LTD. | 1,656,673 | $48,060,000 | 0.48% |